PT - JOURNAL ARTICLE AU - Akomezoghe, Luccheri Ndong AU - M’Bondoukwé, Noé Patrick AU - Mawili Mboumba, Denise Patricia AU - Ndong Ngomo, Jacques Mari AU - Bridy Chesli, Moutombi Ditombi AU - Sibi Matotou, Hadry Roger AU - Migueba, Valentin AU - Bouyou Akotet, Marielle Karine TI - Efficacy and Safety of Albendazole 400 mg for 30 Days in Adults Patients with Low <em>Loa loa</em> Microfilaremia: A Non-Inferiority Randomized Controlled Trial Compared to Ivermectin AID - 10.1101/2024.08.16.24310835 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.16.24310835 4099 - http://medrxiv.org/content/early/2024/08/17/2024.08.16.24310835.short 4100 - http://medrxiv.org/content/early/2024/08/17/2024.08.16.24310835.full AB - Background Loa loa infection is endemic in central African countries like Gabon and in West Africa. Treatment typically involves the use of ivermectin and albendazole, with albendazole often used to reduce microfilaremia in individuals with high microfilaremia before administering ivermectin. This study aims to evaluate the efficacy and safety of albendazole in patients with low microfilaremia.Methodology and principal findings The study was conducted from November 7 to April 1 across 31 villages in the Woleu-Ntem province of northern Gabon. Following a questionnaire, venous blood was collected in EDTA tubes for Loa loa diagnosis. Eligible individuals were randomized into two treatment groups and followed for 30 days. One group received daily albendazole tablets (400 mg), while the other received a single dose of ivermectin (200μg/kg). The study reported a 33.0% prevalence of Loa loa infection in northern Gabon. In the per-protocol analysis, the mean microfilaremia decreased significantly by 82.3% and 90.4% in the ALB and IVM groups, respectively (p˂ 0.001). The risk difference between the treatments was 8.1% [95% CI: 16.8; −0.6%]. For the intention-to-treat analysis, the mean microfilaremia decreased significantly by 82.4% and 90.8% in the ALB and IVM groups, respectively (p˂ 0.001), with a risk difference of 8.4% [95% CI: 16.2; 0.6%]. Eosinophil rates decreased by day 30 in both groups, though not significantly different (p&gt;0.05).Conclusions/Significance The prevalence of Loa loa infection (33.05%) is notably high in northern Gabon. Albendazole demonstrated microfilaricidal activity in individuals with low Loa loa microfilaremia. However, its efficacy appears inferior to that of ivermectin and seems to diminish at very low microfilarial loads.Author summary Loa loa infection is endemic in central African countries, including Gabon, and across West Africa. Despite the absence of specific treatments developed for Loa loa, current therapeutic approaches predominantly rely on diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB). Although ALB is more readily available, it is typically reserved for patients with high microfilaremia due to potential severe adverse effects following treatment with IVM. This study aimed to evaluate the efficacy and safety of ALB as an alternative treatment for patients with low microfilaremia compared to IVM. The findings suggest that ALB could serve as a viable alternative for the treatment of microfilaremic loiasis. Moreover, ALB treatment demonstrated adequate clinical efficacy and safety comparable to that of IVM.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN14889921Funding StatementEuropean and Developing Countries Clinical Trials PartnershipAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of MInistry of Health of Gabon gave ethical approval for this work. The protocol number is 0053/2022/CNER/P/SG.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors